Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

E. U. Suárez,B. Boluda,E. Lavilla,M. Tormo,C. Botella,C. Gil,S. Vives,C. Rodríguez,J. Serrano,M. J. Sayas,P. Martínez-Sánchez,F. Ramos,T. Bernal,L. Algarra,J. M. Bergua-Burgues,J. A. Pérez-Simón,P. Herrera,M. Barrios,V. Noriega-Concepción,J. A. Raposo-Puglia,R. Ayala,E. Barragán,D. Martínez-Cuadrón,M. L. Amigo,J. L. López-Lorenzo,A. Lázaro-García,J. E. Guimaraes,M. Colorado,R. García-Boyero,B. De Rueda-Ciller,M. Foncillas-García,A. Hong,J. Labrador,J. M. Alonso-Dominguez,P. Montesinos,on behalf of the PETHEMA group

DOI: https://doi.org/10.1007/s00277-024-05840-7

2024-06-18

Annals of Hematology

Abstract:FLT3 -ITD and NPM1 mutations are key to defining the genetic risk profile of acute myeloid leukemia (AML). We aimed to assess the prognostic features of the FLT3 -ITD and NPM1 mutations in old and/or unfit individuals with AML treated with non-intensive therapies in the era before azacitidine-venetoclax approbation. The results of various non-intensive regimens were also compared. We conducted a retrospective analysis that included patients treated with different non-intensive regimens, between 2007 and 2020 from PETHEMA AML registry. We compiled 707 patients with a median age of 74 years and median follow-up time of 37.7 months. FLT3 -ITD patients (N = 98) showed a non-significant difference in overall survival (OS) compared to FLT3 -ITD negative-patients (N = 608) ( P = 0.17, median OS was 5 vs 7.3 months respectively). NPM1 -mutated patients (N = 144) also showed a non-significant difference with NPM1 wild type (N = 519) patients ( P = 0.25, median OS 7.2 vs 6.8 respectively). In the Cox regression analysis neither NPM1 nor FLT3 -ITD nor age were significant prognostic variables for OS prediction. Abnormal karyotype and a high leukocyte count showed a statistically significant deleterious effect. Azacitidine also showed better survival compared to FLUGA (low dose cytarabine plus fludarabine). NPM1 and FLT3 -ITD seem to lack prognostic value in older/unfit AML patients treated with non-intensive regimens other than azacitidine-venetoclax combination.

hematology